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Abstract
Malignant melanoma of the conjunctiva (CM) is an uncommon but potentially deadly disorder. Many malignancies
show an increased activity of the epigenetic modifier enhancer of zeste homolog 2 (EZH2). We studied whether
EZH2 is expressed in CM, and whether it may be a target for therapy in this malignancy. Immunohistochemical
analysis showed that EZH2 protein expression was absent in normal conjunctival melanocytes and primary acquired
melanosis, while EZH2 was highly expressed in 13 (50%) of 26 primary CM and seven (88%) of eight lymph node
metastases. Increased expression was positively associated with tumour thickness (p=0.03). Next, we targeted
EZH2 with specific inhibitors (GSK503 and UNC1999) or depleted EZH2 by stable shRNA knockdown in three
primary CM cell lines. Both pharmacological and genetic inactivation of EZH2 inhibited cell growth and colony
formation and influenced EZH2-mediated gene transcription and cell cycle profile in vitro. The tumour suppressor
gene p21/CDKN1A was especially upregulated in CM cells after EZH2 knockdown in CM cells. Additionally, the
potency of GSK503 against CM cells was monitored in zebrafish xenografts. GSK503 profoundly attenuated tumour
growth in CM xenografts at a well-tolerated concentration. Our results indicate that elevated levels of EZH2 are
relevant to CM tumourigenesis and progression, and that EZH2 may become a potential therapeutic target for
patients with CM.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Conjunctival melanoma (CM) is a rare malignancy on
the ocular surface, showing an increasing incidence in
Europe and the United States [1–3]. CMs recur fre-
quently after surgical removal and can lead to death, due
to metastases [4,5]. The melanoma-related death rate
can reach 29% at 10 years [5,6]. Once distant metastases
occur, there are few therapeutic options.
CMs share many characteristics with cutaneous
melanoma, such as the presence of BRAF or NRAS
mutations, which occur in 29% and 18% of CMs,
respectively, and lead to activation of the MAPK path-
way [7]. We recently showed that BRAF inhibitors are
effective on BRAF-mutated CM cell lines [8], and at
least two patients have been treated with these drugs
[9,10]. As resistance to these drugs may develop, there
is a need for alternative targets. In recent years, aware-
ness has increased that not only genetic alterations but
also aberrant epigenetic regulation may be the basis
of malignant disorders. Many epigenetic processes are
regulated through the polycomb repressive complex 2
(PRC2), and overexpression of one of its core catalytic
subunits, enhancer of zeste homolog 2 (EZH2), has been
observed in a broad spectrum of cancer types including
cutaneous melanoma, breast cancer, and endometrial
carcinoma [11,12]. EZH2 is a histone methyltransferase
which catalyses trimethylation of lysine 27 in histone
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and
distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
434 J Cao et al
H3 (H3K27me3); this leads to transcriptional silencing
of many genes, including tumour suppressor genes,
rendering EZH2 a potential oncogene [13,14]. EZH2 is
not expressed in the normal tissues of adults, except in
actively dividing cells, such as stem cells [15]. Somatic
mutations including gain-of-function alterations of
EZH2 have primarily been discovered in haematopoi-
etic malignancies. Currently, drugs that target EZH2
have shown promising preclinical results, and some
phase 1/2 clinical trials using small molecule inhibitors
have been initiated for EZH2 mutant or wild-type
lymphoma [16–18].
Insight into the importance of EZH2 in melanoma
is increasing [19]. Although somatic activating EZH2
mutations occurred in only 3% of cutaneous melanomas
[19], EZH2 is frequently overexpressed in cutaneous
melanoma cells, while its expression is not detectable in
benign naevi, suggesting a role for EZH2 in melanoma
progression [20]. Furthermore, EZH2 depletion or inhi-
bition has been shown to repress tumour growth and
metastasis in a murine model of cutaneous melanoma
[21]. Although in many ways CM resembles cutaneous
melanoma, the study of EZH2 expression and func-
tion in a biological context of CM development is still
missing.
Here, we show that EZH2 expression is absent in
normal conjunctival melanocytes and primary acquired
melanosis (PAM) but elevated in primary tumours and
metastases of CM patients. In addition, we reveal that
pharmacological inhibition of EZH2 activity or genetic
depletion of EZH2 leads to robust anti-cancer effects
in vitro and in vivo. These results indicate that tar-




Paraffin-embedded tissue specimens of nine PAMs, 26
primary CMs, and one lymph node metastasis were
collected through the archives of the Department of
Pathology, Leiden University Medical Centre, Leiden,
from patients who had been diagnosed with a con-
junctival melanocytic lesion between 1990 and 2014.
Paraffin-embedded material of seven lymph node metas-
tases of CM was retrieved from the Department of
Pathology of the Erasmus University Medical Centre.
All specimens contained enough material for the study.
Five normal conjunctival samples were obtained from
uveal melanoma-containing enucleated eyes. The use
of human materials was approved by the Ethical Com-
mittee Board of Leiden University Medical Centre and
allowed by Erasmus University Medical Centre because
it was a retrospective and non-interventional study. The
diagnosis was reviewed, and the original slides were
assessed according to the seventh edition of the AJCC
TNM Cancer Staging Manual [21].
Immunohistochemistry (IHC) staining
and evaluation
IHC was carried out as previously described [22]. In
brief, after hot (100 ∘C) antigen retrieval in a microwave
oven and 1 h cooling to room temperature, sections were
blocked with normal goat serum (1:10, X0907; Dako,
Glostrup, Denmark) for 1 h at room temperature, after
which the slides were incubated with anti-EZH2 mono-
clonal antibody (1:100, 612667; BD Biosciences, Via-
nen, The Netherlands) overnight at 4 ∘C. Thereafter,
slides were incubated with peroxidase-labelled poly-
mer conjugated to a goat anti-mouse secondary antibody
(K4000; Dako), visualized with a NovaRED substrate
kit (SK-4800; Vector Laboratories, Burlingame, CA,
USA), counterstained with haematoxylin, and mounted
with Kaiser’s glycerol gelatine. Human placental tis-
sue served as the positive control. An isotype con-
trol was obtained by replacing the primary antibody
with the mouse IgG1 reagent (X9031; Dako). Evalua-
tion was done by two independent observers (JC and
EJ) in a blinded manner. In cases of divergent scores,
a consensus was reached by simultaneous evaluation.
Images were taken using Philips Image Management
System 2.2. A staining index (SI) system evaluating both
intensity (0= no staining; 1=weak; 2=moderate; and
3= strong) and percentage of cells with nuclear EZH2
staining (1=≤ 10%; 2= 11–50%; and 3≥ 50%) was
used [12,23]. Multiplying intensity and percentage pro-
duced total scores (0–9). After considering the distribu-
tion plots and number of cases, the median (SI= 3) was
set as the cut-off value between low expression and high
expression, as previously described [12,23].
Cell lines, lentiviral transduction, and chemical
reagents
HumanCMcell lines CRMM1 andCRMM2were estab-
lished by G Nareyeck, Essen, Germany [24], and kindly
provided by M Madigan, Sydney, Australia. CM2005.1
was established by S Keijser, LUMC, Leiden, The
Netherlands [25]. Human cutaneous melanoma cell
lines A375 and MEL93.05 were kindly provided by E
Verdegaal, LUMC, Leiden, The Netherlands. The media
and methods of cell culture have been described previ-
ously [8]. Two validated MISSION®shRNA constructs
(TRCN0000040-075 and TRCN0000040-077; Sigma
Aldrich, St Louis, MO, USA) were used to silence
EZH2. Control shRNA vectors were from the same
library, the non-targeting shc002, and the luciferase
targeting shc007. HEK293T cells were transfected with
the shRNA constructs together with helper plasmids
encoding HIV-1 gag-pol, HIV-1 rev, and the VSV-G
envelope, as described previously [26]. To determine
virus titres, p24 antigen levels were determined using
an HIV-1 p24 antigen enzyme-linked immunosorbent
assay (ELISA) kit (ZeptoMetrix Corp, Buffalo, NY,
USA). The CM cell lines were transduced with an MOI
(multiplicity of infection) of 2.0 for 16 h in medium con-
taining 8.0 μg/ml polybrene. Virus-containing medium
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was replaced with fresh medium containing puromycin
(1 μg/ml) for 72 h to select transduced cells. GSK503
(S7804) and UNC1999 (S7165) were purchased from
Selleck Chemicals (Huissen, The Netherlands). All
drugs were dissolved in dimethyl sulphoxide (DMSO)
to obtain a stock solution of 20mM.
Immunoblotting
Protein lysates were extracted using 1.5× SDS sample
buffer (75mM Tris–HCl, pH 6.8; 3% SDS; 15% glyc-
erol). SDS-PAGE was carried out by loading 15–20 μg
of total protein lysate on Mini-PROTEAN TGX Precast
Gels (4–15%; Bio-Rad, Veenendaal, The Netherlands).
Proteins were blotted onto polyvinylidene difluoride
membranes (Immobilon-P; Millipore, Burlington, MA,
USA). Next, membranes were incubated overnight
with primary antibodies (supplementary material, Table
S1) diluted with Odyssey blocking buffer (927-5000;
LI-COR; Westburg BV, Leusden, The Netherlands) at
4 ∘C, and visualized using IRdye-680 or IRdye-800
secondary antibodies (LI-COR). Blots were scanned
and analysed with the Odyssey Infrared Imaging
System (LI-COR). Alternatively, membranes were incu-
bated with horseradish peroxidase (HRP)-conjugated
secondary antibodies and visualized by chemilumines-
cence.
Cell proliferation and colony assay
The in-cell western assay was used to determine the
growth rate, as previously described [8]. Detailed infor-
mation is given in the supplementary material, Supple-
mentary materials and methods.
Flow cytometry, RNA isolation, cDNA synthesis,
and quantitative PCR
Details are provided in the supplementary material,
Supplementary materials and methods, and primer
sequences are shown in the supplementary material,
Table S2.
Fluorescent cell labelling and zebrafish model
To generate CM cells with red fluorescence, cells
were stably transduced with lentivirus expressing both
tdTomato and blasticidin-S, as described previously
[27]. Virus-containing medium was replaced with fresh
medium containing blasticidin-S (2 μg/ml) to select
transduced cells. Transduction of the cells with the
tdTomato-expressing virus did not alter the growth
pattern of parental cells [28].
The (fli:GFP) Casper zebrafish embryos were main-
tained according to standard protocols (http://ZFIN.org,
in the public domain) [29,30], in compliance with Dutch
animal welfare regulations. The research followed the
statement on the use of animals in research as published
by the Association for Research in Vision and Oph-
thalmology and has been described previously [28]. To
test drug toxicity, non-injected 3 days post-fertilization
(dpf) (fli:GFP) Casper zebrafish embryos were put into a
24-well plate; each well contained 1ml of egg water and
different concentrations of GSK503. Six embryos were
put into each well, maintained at 34 ∘C, and monitored
daily until 8 dpf. The test was performed in triplicate
and the media were refreshed every second day. When
the survival was equal to or higher than 80%, the con-
centration was considered non-toxic to the embryos.
After choosing the appropriate concentration, the
same experimental conditions were applied for the treat-
ment of tumour cell-injected embryos. Thus, at 2 dpf,
350–450 cells of CRMM1, CRMM2 or CM2005.1 cells
were injected inside the duct of Cuvier of (fli:GFP)
Casper zebrafish embryos. At 1 day post-injection (dpi),
drug treatment was started and continued until 6 dpi,
completing a 5-day treatment. At 1 and 6 dpi, injected
embryos were anaesthetized with 0.160mg/ml tricaine
(Sigma-Aldrich) to facilitate imaging under a stereo flu-
orescence microscope (LeicaM205FA; LeicaMicrosys-
tems, Amsterdam, The Netherlands.). The red pixels
representing the number of cells inside the embryo were
counted using ImageJ software [30].
Statistical analyses
Statistical analyses were performed with either SPSS
version 23.0 software (SPSS Inc, Chicago, IL, USA)
or R version 2.15.1 [31]. Pearson’s chi-square,
Fisher’s exact, and Mann–Whitney U-tests were
used for comparing categorical or numerical data of
clinico-pathological characteristics. Two-tailed P values
less than or equal to 0.05 were considered statistically
significant. The plots of cell proliferation and cell cycle
profiles were made with GraphPad Prism 6 software
(GraphPad, La Jolla, CA, USA). The IC50 of drugs
was calculated with CompuSyn software (http://www
.combosyn.com), according to relative 5-day growth
inhibition [32]. The effect of GSK503 in vivo was anal-
ysed using a generalized linear model after square-root
transformation of the data.
Results
EZH2 is overexpressed in CMs and metastases
We determined EZH2 expression in CMs using IHC
and analysing the intensity and percentage of positive
cells. Representative samples of the different EZH2
expression patterns in CMs are shown in Figure 1
(clinico-pathological characteristics are listed in
Table 1, and clinical information in the supplemen-
tary material, Table S3). In normal conjunctiva, we
observed some nuclear staining of keratinocytes but not
of melanocytes. EZH2 was also not expressed in PAM
tissues (supplementary material, Table S4). In contrast,
EZH2 was highly expressed in 13 (50%) of the CM
specimens and absent or marginally expressed in the
other 13 (50%) primary CMs. In addition, seven (88%)
out of eight lymph node metastases of CM showed
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Figure 1. Representative images of EZH2 IHC staining in CM. (A) Positive control staining of placental tissue. (B) EZH2-positive keratinocytes
(black arrow), and EZH2-negative melanocytes in the normal conjunctiva (red arrow). (C) EZH2 is absent in primary acquired melanosis. (D)
CM with negative nuclear staining in all tumour cells. (E) CM with weak, (F) moderate, or (G) strong nuclear staining in more than 50% of
tumour cells. (H) Strong nuclear staining in tumour cells in a lymph node metastasis. D and E were considered EZH2-low expression (scored
≤3); F, G, and H were scored >3 and considered EZH2-high expression. Scale bars are 50 μm (original images) and 20 μm (insets). Black
arrows indicate EZH2-positive cells.
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Overexpression of EZH2 in conjunctival melanoma may serve as a target 437
Table 1. Clinico-pathological characteristics according to low and high EZH2 expression
All cases EZH2 low EZH2 high Significance
Characteristic Cases (%) Cases (%) Cases (%) P value
Overall 26 (100) 13 (50) 13 (50)
Sex
Male 11 (42) 8 (62) 3 (23) 0.05*
Female 15 (58) 5 (38) 10 (77)
Age at diagnosis
Median (range), years 60.3 (21.2–86.3) 56.5 (21.2–73.0) 67.1 (48.7–86.3) 0.03**
Tumour size, thickness N= 23 N= 11 N= 12
Median (range), mm 1.0 (0.1–16.0) 0.6 (0.2–2.5) 3.3 (0.1–16.0) 0.03**
Tumour size, LBD N= 23 N= 13 N= 10
Median (range), mm 10.0 (2.0–30.0) 9.0 (2.0–30.0) 11.0 (5.0–20.0) 0.45**
Location
Epibulbar 19 (73) 11 (85) 8 (62) 0.38†
Non-epibulbar 7 (27) 2 (15) 5 (38)
cTNM
T1 19 (73) 11 (85) 8 (62) 0.38†
T2 7 (27) 2 (15) 5 (38)
Local recurrence
No 16 (62) 7 (54) 9 (69) 0.42*
Yes 10 (38) 6 (46) 4 (31)
Distant metastasis
No 23 (88) 12 (92) 11 (85) 1.00†
Yes 3 (12) 1 (8) 2 (15)
LBD= largest basal diameter; cTNM= clinical TNM stage, based on the first occurring conjunctival melanoma.
P value calculation: *Pearson’s chi-square; **Mann–Whitney U-test; †Fisher’s exact test. Italic P values≤0.05. The scoring method for EZH2 is described in the Materials
and methods section.
strong EZH2 expression (supplementary material, Table
S5). In primary tumours, EZH2 expression correlated
positively with tumour thickness (p= 0.03). A high
level of EZH2 expression was correlated with worse
overall survival and tended to be associated with worse
melanoma-related survival (Figure 2). However, EZH2
expression was not correlated with tumour location,
tumour stage, local recurrence or distant metastasis
(Table 1).
Pharmacological inhibition of EZH2 in CM cells
We determined EZH2 protein expression in three CM
cell lines, a cutaneous melanocyte cell culture (07-11),
and two cutaneous melanoma cell lines, one of which
(A375) has previously been used extensively in deter-
mining the function of EZH2 [33]. Compared with
the normal cutaneous melanocytes, all melanoma cell
lines overexpressed EZH2 (Figure 3A). To investigate a
putative growth stimulatory function of EZH2 in CM,
we treated the cells with the small molecule EZH2
inhibitors GSK503 and UNC1999, since these had been
shown to successfully inhibit the function of EZH2 in
lymphoma and cutaneous melanoma in vitro and in vivo
[20,34]. Figure 3B, F shows that the level of H3K27me3
in CM cells decreased following increasing concen-
trations of GSK503 and UNC1999. EZH2 expression
in CRMM2 and CM2005.1 was slightly decreased by
GSK503, and UNC1999 clearly reduced EZH2 expres-
sion in CRMM2 at a high concentration (6 μM). IC50
values are shown in Table 2.
It has been reported that EZH2 depletion increases
p21 expression in cancer cell lines and thereby induces
cellular senescence [35,36]. Therefore, we examined
p21 expression after drug treatment. However, we found
that the p21 protein levels were only marginally ele-
vated in CRMM1 and CM2005.1 cell lines exposed
to either drug. Basal levels of p21 are very high in
CRMM2 and the increase is hard to evaluate. Treatment
for 5 days with GSK503 reduced the relative survival of
CM cells, although the inhibitory effects on CM2005.1
cells required higher concentrations than the other cell
lines (Figure 3C). Similarly, the proliferation of all CM
cell lines was suppressed following UNC1999 treatment
(Figure 3G). The colony formation assay confirmed the
findings of the cell growth assay (supplementary mate-
rial, Figure S1).
Genes such as p14ARF, p16INK4a, p21/CDKN1A,
and p27KIP1 have been described as targets of EZH2
inhibition in several cancer types [35,37]. We therefore
investigated whether GSK503 or UNC1999 affected the
transcription of these genes in CM cells. However, the
mRNA levels of p14ARF, p16INK4a, p21/CDKN1A,
and p27KIP1 were not significantly affected by these
drugs (supplementary material, Figure S2). Neverthe-
less, our results show that CM2005.1 does not express
p14ARF or p16INK4a, while CRMM2 lacks p16INK4a
expression.
To determine the effects of EZH2 inhibition on cell
cycle and apoptosis, we performed flow cytometry
analysis after propidium iodide staining (Figure 3D,
H) and western blot analysis to investigate PARP
cleavage (Figure 3E, I). Flow cytometry analysis of
GSK503-treated CRMM1 and CRMM2 cells demon-
strated a G1 arrest concomitant with S-phase depletion
and slightly increased numbers of sub-G1 cells. In
CM2005.1, on the other hand, we noticed an increase in
the proportion of cells in the G2/M phase (Figure 3D),
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Figure 2. Kaplan–Meier analysis of melanoma-related and overall survival based on EZH2 expression.
also with an increase in the sub-G1 fraction. Some
cleaved PARP could be detected in lysates from treated
CRMM1 and CM2005.1 cells (Figure 3E). Following
UNC1999 treatment, CRMM1 and CRMM2 cells
showed an S-phase reduction concomitant with an
increase of G1-phase cells. Furthermore, more sub-G1
cells were observed, indicating cell death (Figure 3H).
In CM2005.1 cells, UNC1999 exposure did not have
a strong effect on the cell cycle profile, but possibly
the cells progress more slowly through the S-phase as
that fraction is somewhat increased. A clearly increased
sub-G1 fraction was identified, again indicating cell
death. After UNC1999 treatment, no upregulation of
cleaved PARP was observed in any cell line (Figure 3I),
which may indicate that the observed cell death is not
via induction of apoptosis. To determine whether the
observed cell death following UNC1999 treatment was
still correlated with changes in the expression of key
apoptotic proteins, we performed western blot analyses.
Although we did find some effects of UNC1999 treat-
ment on the levels of Mcl-1, Bcl-XL, Bcl-2, PUMA,
Bim, survivin, and E2F1 (supplementary material,
Figure S3), the effects were not consistent in the three
cell lines. Since EZH2 has also been linked to the reg-
ulation of autophagy [38], the lysates of the three CM
cell lines treated for 5 days with GSK503 or UNC1999
were investigated for expression of LC3B-II, a hallmark
of autophagy [39]. Protein expression of LC3B-II was
increased in CM cells upon GSK503 and UNC1999
treatment, although at different levels (Figure 3J),
suggesting the induction of autophagy.
Effect of EZH2 knockdown in CM cells
Next, to genetically validate the findings of catalytic
EZH2 inhibitors, we specifically depleted EZH2
in melanoma cell lines using lentiviral-expressed
short hairpin RNAs (shRNAs). Expression of EZH2
was significantly decreased in sh-EZH2-expressing
cells compared with control transduced cells
(shc002, shc007), correlating with a global decrease
of H3K27me3 (Figure 4A). This confirmed that
H3K27me3 was largely dependent on the presence
of EZH2. Depletion of EZH2 increased p21 protein lev-
els in CRMM1, CRMM2 (shEZH2 20), and CM2005.1,
suggesting that the cellular senescence marker p21
participates in growth repression of CM cell lines.
Activation of p21/CDKN1A transcription was detected
in most EZH2-depleted cells, although some variation
between cell lines and EZH2 shRNAs was observed
(Figure 4B). We also investigated the mRNA expres-
sion of p16INK4a, p14ARF, and p27KIP1, but their
expression was not affected by EZH2 depletion (data
not shown).
Importantly, the in-cell western assay indicated a
lower proliferation of EZH2 shRNA-treated cells com-
pared with control shRNA-treated cells (Figure 4C).
Knockdown of EZH2 also strongly decreased the abil-
ity of CM cells to form colonies (supplementary mate-
rial, Figure S4). Flow cytometry analyses showed that
in CRMM1 and CRMM2, EZH2 knockdown resulted in
S-phase depletion with G1 arrest (Figure 4D). Interest-
ingly, in CM2005.1, EZH2 depletion mainly caused an
accumulation of cells in G2/M. In addition, an increased
sub-G1 fraction was observed in all EZH2-depleted
cells, suggesting that EZH2 protects CM cells from cell
death.
Western blotting showed that EZH2 knockdown
increased the amount of cleaved PARP in CM cell lines.
It should be noted that the full-length PARP expression
in CRMM2 cells upon EZH2 depletion was strongly
reduced, which may suggest that PARP is cleaved and
that the cleaved product is unstable. In general, EZH2
depletion induced some degree of apoptosis in CM
cells, indicating its importance in cell survival. The
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Figure 3. Effect of the EZH2 inhibitors GSK503 and UNC1999 on CM cell lines. (A) Western blot analysis of EZH2 protein in three CM cell
lines, CRMM1, CRMM2, and CM2005.1, and two cutaneous melanoma cell lines, A375 and MEL93.05; 07-11 is a human melanocyte culture.
Western blot analysis of CM cells upon 120 h incubation of GSK503 (B) or UNC1999 (F) treatment. Representative bar graphs show the
proliferation of melanoma cell lines exposed for 120 h to GSK503 (C) or UNC1999 (G), respectively. The intensity (Y axis) was normalized to
DMSO-treated control cells. Data are presented as means ±SEM from one representative experiment. Histograms represent DNA content
(D, H) and western blot analysis of (cleaved) PARP (E, J) following 120 h incubation of GSK503 or UNC1999. (J) LC3B-II levels are increased
following 120 h treatment of GSK503 (G, CRMM1 and CRMM2 at 10 μM, and CM2005.1 at 15 μM) or UNC1999 (U, 6 μM).
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 433–444
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Table 2. Cell growth IC50 of EZH2 inhibitors in CM cell lines
Cell line GSK503 (M) UNC1999 (M)
CRMM1 8.5± 0.4 4.2± 0.3
CRMM2 9.3± 0.7 4.1± 0.4
CM2005.1 15.9± 1.4 4.4± 0.3
Cell viability IC50 values of GSK503 (n= 3) and UNC1999 (n= 2) in CM cell lines
(in-cell western assay) were determined based on relative 5-day survival.
results obtained upon EZH2 depletion are strongly
reminiscent of the data obtained with the GSK503
inhibitor (Figure 3D, E), suggesting that this inhibitor
indeed mainly acts through inhibition of EZH2 activity,
while UNC1999 might have additional activities [40].
Therapeutic effect of GSK503 in a zebrafish model
To confirm the findings obtained in cell culture, we
established a zebrafish model to test the drug GSK503
in vivo. A well-tolerated concentration of GSK503 was
determined as previously described [41]. Concentrations
of GSK503 were non-toxic to the embryos until at least
8 dpf (supplementary material, Figure S5), as over 80%
of the embryos survived during the observation period,
even at the highest concentration (24 μM). Subsequently,
three CM cell lines expressing tomato red were injected
into the duct of Cuvier of (fli:GFP) Casper zebrafish
embryos at 2 dpf, and treatment with 24 μM GSK503
or DMSO diluted in egg water was initiated at 1 dpi
and continued until 6 dpi (5-day treatment). Next, cell
growth and dissemination were scored by counting the
number of red pixels in the embryos. Figure 5 shows that
tumour cells migrated to other areas through the blood
circulation and proliferated. Importantly, the tumour
burden of all three CM cell lines in vivowas significantly
reduced after the 5-day treatment with GSK503. We
tested the difference between the control and the treated
groups of the zebrafish embryos injected with the three
CM cell lines with a generalized linear model: the P
values were 0.015 (CRMM1), 0.002 (CRMM2), and
0.028 (CM2005.1).
Discussion
To the best of our knowledge, this is the first study that
demonstrates the importance of EZH2 in CM. Here, we
report that EZH2 is overexpressed in CM. EZH2 was
expressed on keratinocytes of normal conjunctiva, but
not on cells of melanocytic lineage. This is consistent
with studies of cutaneous melanoma, which similarly
showed that EZH2 is present in epidermal keratinocytes,
but absent or expressed at low level in naevi and epider-
mal melanocytes [20,42]. Interestingly, although many
CMs develop in association with PAM [4], EZH2 was
not expressed in PAM. Importantly, we demonstrate that
EZH2 expression is detected in a significant proportion
of CMs and is positively associated with one of the prog-
nostic factors, tumour thickness [4]. Furthermore, EZH2
was highly expressed in most lymph node metastases.
Taken together, our findings indicate that EZH2 protein
levels are often increased in CM and metastases, and
EZH2may therefore be involved in the pathogenesis and
progression of CM tumours.
Many small molecule inhibitors targeting EZH2
have been developed to block its catalytic activity, i.e.
EZH2-mediated methylation of H3K27. A phase 1/2
clinical trial of tazemetostat (EPZ-6438) is currently
ongoing against advanced solid tumours and B-cell
lymphoma (NCT 01897571). In the present study, we
applied two EZH2 inhibitors, GSK503 and UNC1999,
to CM cell lines. In addition, we utilized genetic knock-
down to confirm the findings of the pharmacological
depletion of EZH2. Interestingly, expression of the
tumour suppressor gene p21/CDKN1A was more con-
vincingly upregulated in EZH2-knockdown CM cells
than in inhibitor-treated cells, suggesting that EZH2 has
function(s) in transcription regulation independent of
its catalytic activity. It is known that the mechanisms
of EZH2 oncogenic activity are cancer type-dependent,
including the canonical role of EZH2 in gene silencing
in cutaneous melanoma and colon cancer, and the
non-canonical function of EZH2 that affects other
pathways in a histone methylation-independent manner.
For example, EZH2 can trigger NF-κB signalling in
basal-like breast cancer and transcriptionally co-activate
the androgen receptor in castration-resistant prostate
cancer [43,44]. Further studies are warranted to eluci-
date the function(s) of EZH2 in CM. Regarding the cell
cycle profile and apoptosis, drug treatment and RNA
interference (RNAi) similarly resulted in G1 arrest and
S-phase depletion in CRMM1 and CRMM2. GSK503
and UNC1999 appeared to induce cell death via partly
different mechanisms. Similar to the genetic depletion
of EZH2, the GSK503 inhibitor activated apoptosis and
possibly some autophagy. However, increased caspase
activity as monitored by PARP cleavage could not be
detected upon UNC1999 treatment and no consistent
effect on the level of several key proteins in apoptotic
pathways could be detected, but our results suggest
induction of autophagy. Different patterns of cell death
displayed by these treatments suggest that pharma-
ceutical inhibition cannot totally mimic the EZH2
knockdown in this scenario. Discrepancies between
genetic knockdown and enzymatic inhibitors of EZH2
on biological outcome have been described before: it
was reported that catalytic inhibition of EZH2 using
GSK343 and GSK126 induced no or modest expres-
sion of interferon gamma receptor 1 despite effective
inhibition of H3K27me3 in a prostate cancer cell line,
in contrast to depletion of EZH2 expression [45]. Sim-
ilarly, it was found that SWI/SNF-mutant cancer lines
are more sensitive to EZH2 knockdown than to catalytic
inhibitors [46]. Regarding the autophagy context, the
accumulation of LC3B-II may indicate that EZH2
inhibitors induce autophagy in CM cells, although
induction of autophagy may either increase or repress
cell growth, depending on the stage of tumourigenesis
and mutational and oncogenic background [47]. Hsieh
et al have shown that the promotion of cell death by
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Figure 4. EZH2 knockdown reduces H3K27me3, elevates p21 expression, suppresses cell growth, and induces cell cycle arrest and apoptosis
in CM. (A) The expression of EZH2, H3K27me3, and cell cycle regulatory protein p21 was determined upon EZH2 depletion using shEZH2
18, shEZH2 20, and compared with control shRNAs (shc002 and shc007) 72 h after puromycin selection. (B) The mRNA expression of p21
was increased upon EZH2 knockdown. (C) Representative growth curves of CM cell lines and the A375 cell line after EZH2 knockdown by
specific EZH2 shRNAs compared with control shRNAs. Error bars indicate the standard deviation. (D) Histograms show the percentages of
CRMM1, CRMM2, and CM2005.1 cells in specific cell cycle phases, and western blot analyses (E) (cleaved) PARP in CM cells upon EZH2
knockdown.
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Figure 5. GSK503 suppresses the growth of CM cell lines in a zebrafish model. CM cells were labelled with tomato red (red) and injected
into the duct of Cuvier at 2 dpf in (fli:GFP) Casper zebrafish embryos, which have a green vasculature. The images were taken at 6 dpi. (A,
black) Representative stereo fluorescent images (original magnification: 20 ×) show inhibition of tumour growth after exposure to 24 μM
GSK503. (B, black) Number of red pixels represent tumour cells with DMSO or GSK503 treatment in CM xenografts. Each point indicates
one embryo and its corresponding pixel count. Statistical significance was calculated by the generalized linear model and P values are
indicated as follows: *p< 0.05, **p< 0.01. NCRMM1/DMSO = 30, NCRMM1/GSK503 = 22, NCRMM2/DMSO = 28, NCRMM2/GSK503 = 23, NCM2005.1/DMSO = 25,
NCM2005.1/GSK503 = 18.
autophagy upon treatment with GSK343 or UNC1999
occurred independently of EZH2 inhibition [40]. This
may explain why EZH2 knockdown and UNC1999
treatment have partly distinct effects.
Our newly developed zebrafish xenograft model
allowed the tumour cells to disseminate, and therefore
served as an efficient model of metastatic spread. After
inoculation into the blood circulation, tumour cells
spread to the head and tail of the zebrafish and prolif-
erated, allowing further drug tests. GSK503 profoundly
reduced the growth of CM cells at a well-tolerated
concentration. To the best of our knowledge, this is the
first report using an animal model to test an epigenetic
inhibitor in CM. Although one might question the rel-
evance of a zebrafish model for human patients, Howe
et al recently showed that approximately 71% of human
genes have a corresponding zebrafish ortholog using
the Zv9 assembly. Conversely, 69% of zebrafish genes
have at least one human ortholog [48]. Integrins and
other adhesion molecules form a critical adhesion point
for cancer cells and play a crucial role in the metastatic
initiation of a plethora of cancers [49]. While integrins
enable extracellular matrix interactions required for
metastatic initiation, cadherin molecules function as
homotypic cell–cell adhesion molecules. Cadherins
predominantly play a role in metastatic outgrowth
and progression [50]. In many solid tumours, loss of
E-cadherin is seen as a key turning point in disease pro-
gression enabling cells to dissociate from the primary
tumour and metastasize [51]. Zebrafish integrins are
in general highly homologous to their human counter-
parts, whereas the functional majority of cadherins are
conserved in all metazoans [52].
Overall, our results demonstrate that EZH2 is over-
expressed in CM and lymph node metastases compared
with normal conjunctival melanocytes and PAM, and
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that high EZH2 protein levels are associatedwith tumour
thickness and overall survival. Both pharmaceutical
compounds ands RNAi targeting EZH2 repressed the
growth of CM cells in culture and in vivo. Taken
together, these data reveal that EZH2-targeted therapy
may be a potential therapeutic strategy for patients
with CM.
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